 | • レポートコード：B-GIR08C3858 • 出版社/出版日：GlobalInfoResearch / 2019年8月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール • 産業分類：Pharma & Healthcare |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、多発性骨髄腫に対するモノクローナル抗体の世界市場について調べ、まとめました。種類別セグメントは、エロツズマブ、ダラツムマブ、シルツキシマブ、ダセツズマブ、リツキシマブ、その他等、用途別セグメントは、自己免疫疾患、腫瘍学、代謝性疾患、眼科学、循環器疾患、感染症、神経疾患、呼吸器疾患、その他等に区分しました。多発性骨髄腫に対するモノクローナル抗体の世界市場概観、企業動向、企業別多発性骨髄腫に対するモノクローナル抗体シェア、市場規模推移、市場規模予測（2019年-2024年）、主要地域分析（北米、ヨーロッパ、アジア等）、主要国分析（日本、中国、アメリカ等）データなどの情報が含まれています。 ・多発性骨髄腫に対するモノクローナル抗体の市場概観 ・多発性骨髄腫に対するモノクローナル抗体の企業概要（事業概要、製品種類、販売量、価格、売上、市場シェア等） ・多発性骨髄腫に対するモノクローナル抗体の企業別販売動向、市場シェア、市場集中度、競争動向 ・多発性骨髄腫に対するモノクローナル抗体の世界市場規模 ・多発性骨髄腫に対するモノクローナル抗体の北米市場分析（アメリカ、カナダ、メキシコ等） ・多発性骨髄腫に対するモノクローナル抗体のアメリカ市場規模推移 ・多発性骨髄腫に対するモノクローナル抗体のカナダ市場規模推移 ・多発性骨髄腫に対するモノクローナル抗体のメキシコ市場規模推移 ・多発性骨髄腫に対するモノクローナル抗体のヨーロッパ市場分析（ドイツ、イギリス、ロシア、フランス、イタリア等） ・多発性骨髄腫に対するモノクローナル抗体のドイツ市場規模推移 ・多発性骨髄腫に対するモノクローナル抗体のイギリス市場規模推移 ・多発性骨髄腫に対するモノクローナル抗体のロシア市場規模推移 ・多発性骨髄腫に対するモノクローナル抗体のアジア太平洋市場分析（日本、中国、韓国、インド、東南アジア等） ・多発性骨髄腫に対するモノクローナル抗体の日本市場規模推移 ・多発性骨髄腫に対するモノクローナル抗体の中国市場規模推移 ・多発性骨髄腫に対するモノクローナル抗体の韓国市場規模推移 ・多発性骨髄腫に対するモノクローナル抗体のインド市場規模推移 ・多発性骨髄腫に対するモノクローナル抗体の東南アジア市場規模推移 ・多発性骨髄腫に対するモノクローナル抗体の南米市場分析（ブラジル、アルゼンチン等） ・多発性骨髄腫に対するモノクローナル抗体の中東・アフリカ市場分析（サウジアラビア、UAE、南アフリカ等） ・多発性骨髄腫に対するモノクローナル抗体の種類別分析/販売量、売上、市場シェア（エロツズマブ、ダラツムマブ、シルツキシマブ、ダセツズマブ、リツキシマブ、その他） ・多発性骨髄腫に対するモノクローナル抗体の用途別分析/市場規模（自己免疫疾患、腫瘍学、代謝性疾患、眼科学、循環器疾患、感染症、神経疾患、呼吸器疾患、その他） ・多発性骨髄腫に対するモノクローナル抗体の市場予測2019年-2024年（地域別予測、種類別予測、用途別予測） ・多発性骨髄腫に対するモノクローナル抗体の販売チャネル・代理店・貿易業者・ディーラー分析 |
Scope of the Report:
The global Monoclonal Antibody for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Monoclonal Antibody for Multiple Myeloma.
Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
This report studies the Monoclonal Antibody for Multiple Myeloma market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Monoclonal Antibody for Multiple Myeloma market by product type and applications/end industries.
Market Segment by Companies, this report covers
Bristol Myers Squibb
Abbvie
Janssen Biotech
Karyopharm Therapeutics
PDL BioPharma
Roche
Seattle Genetics
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Elotuzumab
Daratumumab
Siltuximab
Dacetuzumab
Rituximab
Other
Market Segment by Applications, can be divided into
Hospital
Drug Center
Clinic
Other
Table of Contents
1 Monoclonal Antibody for Multiple Myeloma Market Overview
1.1 Product Overview and Scope of Monoclonal Antibody for Multiple Myeloma
1.2 Classification of Monoclonal Antibody for Multiple Myeloma by Types
1.2.1 Global Monoclonal Antibody for Multiple Myeloma Revenue Comparison by Types (2019-2024)
1.2.2 Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Types in 2018
1.2.3 Elotuzumab
1.2.4 Daratumumab
1.2.5 Siltuximab
1.2.6 Dacetuzumab
1.2.7 Rituximab
1.2.8 Other
1.3 Global Monoclonal Antibody for Multiple Myeloma Market by Application
1.3.1 Global Monoclonal Antibody for Multiple Myeloma Market Size and Market Share Comparison by Applications (2014-2024)
1.3.2 Hospital
1.3.3 Drug Center
1.3.4 Clinic
1.3.5 Other
1.4 Global Monoclonal Antibody for Multiple Myeloma Market by Regions
1.4.1 Global Monoclonal Antibody for Multiple Myeloma Market Size (Million USD) Comparison by Regions (2014-2024)
1.4.1 North America (USA, Canada and Mexico) Monoclonal Antibody for Multiple Myeloma Status and Prospect (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Monoclonal Antibody for Multiple Myeloma Status and Prospect (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Monoclonal Antibody for Multiple Myeloma Status and Prospect (2014-2024)
1.4.4 South America (Brazil, Argentina, Colombia) Monoclonal Antibody for Multiple Myeloma Status and Prospect (2014-2024)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Monoclonal Antibody for Multiple Myeloma Status and Prospect (2014-2024)
1.5 Global Market Size of Monoclonal Antibody for Multiple Myeloma (2014-2024)
2 Manufacturers Profiles
2.1 Bristol Myers Squibb
2.1.1 Business Overview
2.1.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.2 Abbvie
2.2.1 Business Overview
2.2.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Abbvie Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.3 Janssen Biotech
2.3.1 Business Overview
2.3.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Janssen Biotech Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.4 Karyopharm Therapeutics
2.4.1 Business Overview
2.4.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.5 PDL BioPharma
2.5.1 Business Overview
2.5.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 PDL BioPharma Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.6 Roche
2.6.1 Business Overview
2.6.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Roche Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
2.7 Seattle Genetics
2.7.1 Business Overview
2.7.2 Monoclonal Antibody for Multiple Myeloma Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Seattle Genetics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
3 Global Monoclonal Antibody for Multiple Myeloma Market Competition, by Players
3.1 Global Monoclonal Antibody for Multiple Myeloma Revenue and Share by Players (2014-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 Monoclonal Antibody for Multiple Myeloma Players Market Share
3.2.2 Top 10 Monoclonal Antibody for Multiple Myeloma Players Market Share
3.3 Market Competition Trend
4 Global Monoclonal Antibody for Multiple Myeloma Market Size by Regions
4.1 Global Monoclonal Antibody for Multiple Myeloma Revenue and Market Share by Regions
4.2 North America Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.3 Europe Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.4 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.5 South America Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
4.6 Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5 North America Monoclonal Antibody for Multiple Myeloma Revenue by Countries
5.1 North America Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
5.2 USA Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5.3 Canada Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
5.4 Mexico Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6 Europe Monoclonal Antibody for Multiple Myeloma Revenue by Countries
6.1 Europe Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
6.2 Germany Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.3 UK Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.4 France Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.5 Russia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
6.6 Italy Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Countries
7.1 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
7.2 China Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.3 Japan Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.4 Korea Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.5 India Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
7.6 Southeast Asia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8 South America Monoclonal Antibody for Multiple Myeloma Revenue by Countries
8.1 South America Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
8.2 Brazil Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8.3 Argentina Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
8.4 Colombia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9 Middle East and Africa Revenue Monoclonal Antibody for Multiple Myeloma by Countries
9.1 Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
9.2 Saudi Arabia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.3 UAE Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.4 Egypt Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.5 Nigeria Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
9.6 South Africa Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
10 Global Monoclonal Antibody for Multiple Myeloma Market Segment by Type
10.1 Global Monoclonal Antibody for Multiple Myeloma Revenue and Market Share by Type (2014-2019)
10.2 Global Monoclonal Antibody for Multiple Myeloma Market Forecast by Type (2019-2024)
10.3 Elotuzumab Revenue Growth Rate (2014-2024)
10.4 Daratumumab Revenue Growth Rate (2014-2024)
10.5 Siltuximab Revenue Growth Rate (2014-2024)
10.6 Dacetuzumab Revenue Growth Rate (2014-2024)
10.7 Rituximab Revenue Growth Rate (2014-2024)
10.8 Other Revenue Growth Rate (2014-2024)
11 Global Monoclonal Antibody for Multiple Myeloma Market Segment by Application
11.1 Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Application (2014-2019)
11.2 Monoclonal Antibody for Multiple Myeloma Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2014-2019)
11.4 Drug Center Revenue Growth (2014-2019)
11.5 Clinic Revenue Growth (2014-2019)
11.6 Other Revenue Growth (2014-2019)
12 Global Monoclonal Antibody for Multiple Myeloma Market Size Forecast (2019-2024)
12.1 Global Monoclonal Antibody for Multiple Myeloma Market Size Forecast (2019-2024)
12.2 Global Monoclonal Antibody for Multiple Myeloma Market Forecast by Regions (2019-2024)
12.3 North America Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.4 Europe Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.5 Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.6 South America Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
12.7 Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
Figure Monoclonal Antibody for Multiple Myeloma Picture
Table Product Specifications of Monoclonal Antibody for Multiple Myeloma
Table Global Monoclonal Antibody for Multiple Myeloma and Revenue (Million USD) Market Split by Product Type
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Types in 2018
Figure Elotuzumab Picture
Figure Daratumumab Picture
Figure Siltuximab Picture
Figure Dacetuzumab Picture
Figure Rituximab Picture
Figure Other Picture
Table Global Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) by Application (2014-2024)
Figure Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Applications in 2018
Figure Hospital Picture
Figure Drug Center Picture
Figure Clinic Picture
Figure Other Picture
Table Global Market Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) Comparison by Regions 2014-2024
Figure North America Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Europe Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure South America Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) and Growth Rate (2014-2024)
Table Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Type and Applications
Table Bristol Myers Squibb Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Abbvie Basic Information, Manufacturing Base and Competitors
Table Abbvie Monoclonal Antibody for Multiple Myeloma Type and Applications
Table Abbvie Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Janssen Biotech Basic Information, Manufacturing Base and Competitors
Table Janssen Biotech Monoclonal Antibody for Multiple Myeloma Type and Applications
Table Janssen Biotech Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Karyopharm Therapeutics Basic Information, Manufacturing Base and Competitors
Table Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Type and Applications
Table Karyopharm Therapeutics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table PDL BioPharma Basic Information, Manufacturing Base and Competitors
Table PDL BioPharma Monoclonal Antibody for Multiple Myeloma Type and Applications
Table PDL BioPharma Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Roche Basic Information, Manufacturing Base and Competitors
Table Roche Monoclonal Antibody for Multiple Myeloma Type and Applications
Table Roche Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Seattle Genetics Basic Information, Manufacturing Base and Competitors
Table Seattle Genetics Monoclonal Antibody for Multiple Myeloma Type and Applications
Table Seattle Genetics Monoclonal Antibody for Multiple Myeloma Revenue, Gross Margin and Market Share (2017-2018)
Table Global Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) by Players (2014-2019)
Table Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Players (2014-2019)
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Players in 2017
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Players in 2018
Figure Global Top 5 Players Monoclonal Antibody for Multiple Myeloma Revenue Market Share in 2018
Figure Global Top 10 Players Monoclonal Antibody for Multiple Myeloma Revenue Market Share in 2018
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) and Growth Rate (%) (2014-2019)
Table Global Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) by Regions (2014-2019)
Table Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Regions (2014-2019)
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Regions (2014-2019)
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Regions in 2018
Figure North America Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Europe Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure South America Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table North America Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
Table North America Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure North America Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure North America Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure USA Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Canada Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Mexico Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Europe Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) by Countries (2014-2019)
Figure Europe Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Europe Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure Germany Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure UK Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure France Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Russia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Italy Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) by Countries (2014-2019)
Figure Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure China Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Japan Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Korea Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure India Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Southeast Asia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table South America Monoclonal Antibody for Multiple Myeloma Revenue by Countries (2014-2019)
Table South America Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure South America Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure South America Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure Brazil Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Argentina Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Colombia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) by Countries (2014-2019)
Table Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries (2014-2019)
Figure Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue Market Share by Countries in 2018
Figure Saudi Arabia Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure UAE Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Egypt Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure Nigeria Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Figure South Africa Monoclonal Antibody for Multiple Myeloma Revenue and Growth Rate (2014-2019)
Table Global Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) by Type (2014-2019)
Table Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Type (2014-2019)
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Type (2014-2019)
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Type in 2018
Table Global Monoclonal Antibody for Multiple Myeloma Revenue Forecast by Type (2019-2024)
Figure Global Monoclonal Antibody for Multiple Myeloma Market Share Forecast by Type (2019-2024)
Figure Global Elotuzumab Revenue Growth Rate (2014-2019)
Figure Global Daratumumab Revenue Growth Rate (2014-2019)
Figure Global Siltuximab Revenue Growth Rate (2014-2019)
Figure Global Dacetuzumab Revenue Growth Rate (2014-2019)
Figure Global Rituximab Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Table Global Monoclonal Antibody for Multiple Myeloma Revenue by Application (2014-2019)
Table Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Application (2014-2019)
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Application (2014-2019)
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue Share by Application in 2018
Table Global Monoclonal Antibody for Multiple Myeloma Revenue Forecast by Application (2019-2024)
Figure Global Monoclonal Antibody for Multiple Myeloma Market Share Forecast by Application (2019-2024)
Figure Global Hospital Revenue Growth Rate (2014-2019)
Figure Global Drug Center Revenue Growth Rate (2014-2019)
Figure Global Clinic Revenue Growth Rate (2014-2019)
Figure Global Other Revenue Growth Rate (2014-2019)
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) and Growth Rate Forecast (2019-2024)
Table Global Monoclonal Antibody for Multiple Myeloma Revenue (Million USD) Forecast by Regions (2019-2024)
Figure Global Monoclonal Antibody for Multiple Myeloma Revenue Market Share Forecast by Regions (2019-2024)
Figure North America Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure Europe Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure Asia-Pacific Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure South America Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
Figure Middle East and Africa Monoclonal Antibody for Multiple Myeloma Revenue Market Forecast (2019-2024)
多発性骨髄腫用標的治療薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Targeted Drugs for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially…- 世界のモノクローナル抗体療法市場：市場規模・現状・予測 Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. Monoclonal antibodies can have monovalent affinity, in that they bind to the same epitope (the part of an antigen that is recognized by the antibody). In contrast, polyclonal ant…
- 多発性骨髄腫プロテアソーム阻害薬の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Proteasome Inhibitors for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, esp…
- 世界の多発性骨髄腫の治療市場：市場規模・現状・予測 Multiple myeloma is a cancer formed due to malignant plasma cells. Normal plasma cells are found in the bone marrow and are an important part of the immune system. Plasma cells helps to fight infections by making antibodies that recognize and attack germs. Multiple myeloma causes cancer cells to acc…
- 多発性骨髄腫用免疫調節剤の世界市場予測 2024年：企業別、地域別、種類・用途別（～2024） Scope of the Report: The global Immunomodulator for Multiple Myeloma market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especiall…